Cargando…
Left atrial appendage closure device implantation via transhepatic vascular access: a case report
BACKGROUND: In patients with non-valvular atrial fibrillation, an estimated 90% of thrombi are located in the left atrial appendage. The WATCHMAN device is a left atrial appendage closure device that is an alternative therapeutic option to reduce the risk of systemic embolization in patients who are...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891241/ https://www.ncbi.nlm.nih.gov/pubmed/33628994 http://dx.doi.org/10.1093/ehjcr/ytaa400 |
_version_ | 1783652659001032704 |
---|---|
author | Zare, Pegah Rechani, Luis Smithson, Shaun |
author_facet | Zare, Pegah Rechani, Luis Smithson, Shaun |
author_sort | Zare, Pegah |
collection | PubMed |
description | BACKGROUND: In patients with non-valvular atrial fibrillation, an estimated 90% of thrombi are located in the left atrial appendage. The WATCHMAN device is a left atrial appendage closure device that is an alternative therapeutic option to reduce the risk of systemic embolization in patients who are intolerant of long-term oral anticoagulation. It can be deployed in the left atrial appendage using a transseptal approach via the femoral vein. Transhepatic venous access is an alternative route for the delivery of the device in a patient with difficult vascular access. CASE SUMMARY: An 81-year-old man with persistent non-valvular atrial fibrillation, heart failure with reduced ejection fraction (HFrEF), and diabetes mellitus was deemed a poor candidate for anticoagulation due to recurrent falls and gastrointestinal bleeding. He was selected for a left atrial appendage closure. The initial procedure was aborted after significant resistance to device advancement was encountered in the right femoral vein. Lower extremity venography demonstrated totally occluded femoral and iliac veins bilaterally. The decision was made to implant the device via a transhepatic approach. The procedure had no complications and the patient was discharged on rivaroxaban and aspirin after 3 days. DISCUSSION: Transhepatic venous access is a viable option in patients with poor femoral access for implantation of the WATCHMAN device. It can be done safely. Knowledge of this procedural alternative can greatly enhance patient care. |
format | Online Article Text |
id | pubmed-7891241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-78912412021-02-23 Left atrial appendage closure device implantation via transhepatic vascular access: a case report Zare, Pegah Rechani, Luis Smithson, Shaun Eur Heart J Case Rep Case Reports BACKGROUND: In patients with non-valvular atrial fibrillation, an estimated 90% of thrombi are located in the left atrial appendage. The WATCHMAN device is a left atrial appendage closure device that is an alternative therapeutic option to reduce the risk of systemic embolization in patients who are intolerant of long-term oral anticoagulation. It can be deployed in the left atrial appendage using a transseptal approach via the femoral vein. Transhepatic venous access is an alternative route for the delivery of the device in a patient with difficult vascular access. CASE SUMMARY: An 81-year-old man with persistent non-valvular atrial fibrillation, heart failure with reduced ejection fraction (HFrEF), and diabetes mellitus was deemed a poor candidate for anticoagulation due to recurrent falls and gastrointestinal bleeding. He was selected for a left atrial appendage closure. The initial procedure was aborted after significant resistance to device advancement was encountered in the right femoral vein. Lower extremity venography demonstrated totally occluded femoral and iliac veins bilaterally. The decision was made to implant the device via a transhepatic approach. The procedure had no complications and the patient was discharged on rivaroxaban and aspirin after 3 days. DISCUSSION: Transhepatic venous access is a viable option in patients with poor femoral access for implantation of the WATCHMAN device. It can be done safely. Knowledge of this procedural alternative can greatly enhance patient care. Oxford University Press 2020-12-02 /pmc/articles/PMC7891241/ /pubmed/33628994 http://dx.doi.org/10.1093/ehjcr/ytaa400 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Case Reports Zare, Pegah Rechani, Luis Smithson, Shaun Left atrial appendage closure device implantation via transhepatic vascular access: a case report |
title | Left atrial appendage closure device implantation via transhepatic vascular access: a case report |
title_full | Left atrial appendage closure device implantation via transhepatic vascular access: a case report |
title_fullStr | Left atrial appendage closure device implantation via transhepatic vascular access: a case report |
title_full_unstemmed | Left atrial appendage closure device implantation via transhepatic vascular access: a case report |
title_short | Left atrial appendage closure device implantation via transhepatic vascular access: a case report |
title_sort | left atrial appendage closure device implantation via transhepatic vascular access: a case report |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891241/ https://www.ncbi.nlm.nih.gov/pubmed/33628994 http://dx.doi.org/10.1093/ehjcr/ytaa400 |
work_keys_str_mv | AT zarepegah leftatrialappendageclosuredeviceimplantationviatranshepaticvascularaccessacasereport AT rechaniluis leftatrialappendageclosuredeviceimplantationviatranshepaticvascularaccessacasereport AT smithsonshaun leftatrialappendageclosuredeviceimplantationviatranshepaticvascularaccessacasereport |